Literature DB >> 9014747

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.

S Fujino1, T Enokibori, N Tezuka, Y Asada, S Inoue, H Kato, A Mori.   

Abstract

Epidermal growth factor receptor (EGFR) was measured using a competitive radioligand binding assay in membrane preparations from 74 primary human non-small cell lung cancer (NSCLC) tissues and 20 pathologically normal peripheral lung tissues. The mean EGFR level in tumours was 30.38 fmol/mg (+/-41.95 S.D.) of membrane protein (mg.p), significantly higher (P = 0.00016) than in normal tissues (mean, 10.26 +/- 10.02 fmol/mg.p). The mean EGFR concentration was also significantly higher in pathological stage IV tissue than in stages I (P = 0.049) and II (P = 0.040), and the mean EGFR concentration was significantly higher in cases with mediastinal involvement than in cases without it (P = 0.029). The mean EGFR level was higher in DNA aneuploid and multiploid cases than in DNA diploid cases, but there was no significant difference. No significant relationships were found to exist between receptor concentrations and pathological tumour size or histological type, or patient gender or age. From the above findings, a possible prognostic role for EGFR in primary NSCLC should be investigated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014747     DOI: 10.1016/s0959-8049(96)00243-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  34 in total

Review 1.  Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Authors:  Filip Janku; David J Stewart; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

2.  Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.

Authors:  Mario Acunzo; Giulia Romano; Dario Palmieri; Alessandro Laganá; Michela Garofalo; Veronica Balatti; Alessandra Drusco; Mario Chiariello; Patrick Nana-Sinkam; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 3.  Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.

Authors:  Eileen Mannion; J J Gilmartin; Paul Donnellan; Maccon Keane; Dympna Waldron
Journal:  Support Care Cancer       Date:  2014-02-22       Impact factor: 3.603

4.  Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC).

Authors:  Emad Shash; Fedro Alessandro Peccatori; Hatem A Azim
Journal:  J Thorac Dis       Date:  2011-03       Impact factor: 2.895

5.  Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

Authors:  David E Gerber; David A Boothman; Farjana J Fattah; Ying Dong; Hong Zhu; Rachel A Skelton; Laurin L Priddy; Peggy Vo; Jonathan E Dowell; Venetia Sarode; Richard Leff; Claudia Meek; Yang Xie; Joan H Schiller
Journal:  Lung Cancer       Date:  2015-10-09       Impact factor: 5.705

6.  Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

Authors:  Matias Casás-Selves; Jihye Kim; Zhiyong Zhang; Barbara A Helfrich; Dexiang Gao; Christopher C Porter; Hannah A Scarborough; Paul A Bunn; Daniel C Chan; Aik Choon Tan; James DeGregori
Journal:  Cancer Res       Date:  2012-06-27       Impact factor: 12.701

7.  miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression.

Authors:  Caifeng Liu; Jun Li; Wei Wang; Xingyang Zhong; Feng Xu; Junhua Lu
Journal:  Cell Cycle       Date:  2020-04-14       Impact factor: 4.534

8.  Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis.

Authors:  W Hilbe; S Dirnhofer; F Oberwasserlechner; W Eisterer; K Ammann; T Schmid; G Hilbe; J Thaler; E Wöll
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

9.  EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab.

Authors:  Chad A Reade; Apar Kishor Ganti
Journal:  Biologics       Date:  2009-07-13

10.  Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma.

Authors:  Jin-Hee Ahn; Sang-We Kim; Seung-Mo Hong; Cheolwon Suh; Woo Kun Kim; In Chul Lee; Jung-Shin Lee
Journal:  J Korean Med Sci       Date:  2004-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.